# Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

> **NCT01429116** · PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 200 (estimated)

## Conditions studied

- Non-24-Hour Sleep-Wake Disorder

## Interventions

- **DRUG:** tasimelteon

## Key facts

- **NCT ID:** NCT01429116
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2015-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01429116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01429116, "Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01429116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*